Ifosfamide in the treatment of soft tissue sarcomas.
Ifosfamide is one of the three most active agents in the treatment of soft tissue sarcomas. Ifosfamide-induced urothelial toxicity has been adequately controlled with the use of hydration and the uroprotective agent mesna. This is a review of pilot and phase I and II studies of ifosfamide as a single agent and randomized trials of combination chemotherapy regimens incorporating ifosfamide in the treatment of soft tissue sarcomas. Issues of schedule and dose of ifosfamide will be addressed as well.
Connelly
E F
EF
Department of Hematology/Medical Oncology, Cleveland Clinic Foundation Cancer Center, OH 44195, USA.
Budd
G T
GT
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004334:Drug Administration Schedule; D005440:Fluid Therapy; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015080:Mesna / Q000627:therapeutic use; D010865:Pilot Projects; D016032:Randomized Controlled Trials as Topic; D012509:Sarcoma / Q000188:drug therapy*; D014551:Urinary Tract / Q000187:drug effects
D018906:Antineoplastic Agents, Alkylating; D015080:Mesna; D007069:Ifosfamide